Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Helicon CEO Peter Abrahamson On Exploiting Niche Markets In China: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

Perth, Australia-based Helicon was established in 2003 to identify and exploit niche market opportunities in the specialty pharmaceutical and health care markets of China and North Asia. The company has licensed exclusive marketing rights for four products: Volplex, Collatamp, MedWrap with Microban and Recell. PharmAsia News' Australian bureau recently sat down with Helicon CEO Peter Abrahamson to discuss the company's business strategy in China.
Advertisement

Related Content

Stranded Pigs Rescued By NZ Biotech, Helicon SFDA Approval For Skin Regeneration Device, Arana Ramps Up R&D - Australia/New Zealand Roundup
Stranded Pigs Rescued By NZ Biotech, Helicon SFDA Approval For Skin Regeneration Device, Arana Ramps Up R&D - Australia/New Zealand Roundup
Advertisement
UsernamePublicRestriction

Register

SC068555

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel